SCHEMBL12988694

SCHEMBL12988694

CCCc1nn(C)c2c(=O)nc(-c3cc(S(=O)(=O)N4CC[N+](C)(COC(C)=O)CC4)ccc3OCC)[nH]c12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE5A O76074 20/20 0.58
▸ PDE3B Q13370 3/20 0.58
▸ PDE3A Q14432 3/20 0.58
▸ ABCC4 O15439 2/20 0.58
▸ PDE2A O00408 1/20 0.58
▸ ABCC5 O15440 1/20 0.58
▸ PDE6D O43924 1/20 0.58
▸ PDE8A O60658 1/20 0.58
▸ PDE9A O76083 1/20 0.58
▸ ABCB11 O95342 1/20 0.58
▸ CYP3A4 P08684 1/20 0.58
▸ HTR1A P08908 1/20 0.58
▸ PDE6A P16499 1/20 0.58
▸ PDE6G P18545 1/20 0.58
▸ PDE4A P27815 1/20 0.58
▸ ADORA2A P29274 1/20 0.58
▸ ADORA1 P30542 1/20 0.58
▸ ADRA1A P35348 1/20 0.58
▸ PDE6B P35913 1/20 0.58
▸ PDE6C P51160 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL12989833 0.99 PDE5A (0.58) PDE5APDE3BPDE3AABCC4PDE2A
SCHEMBL17063188 0.98 PDE5A (0.56) PDE5APDE3BPDE3AABCC4PDE2A
SCHEMBL13195833 0.93 PDE5A (0.57) PDE5APDE3BPDE3AABCC4PDE2A
Iodide SCHEMBL15638726 0.93 PDE5A (0.56) PDE5APDE3BPDE3AABCC4PDE2A
SCHEMBL12989194 0.92 PDE5A (0.56) PDE5APDE3BPDE3AABCC4PDE2A
Iodide SCHEMBL15640063 0.91 PDE5A (0.55) PDE5APDE3BPDE3AABCC4PDE2A
SCHEMBL16986497 0.91 PDE5A (0.55) PDE5APDE3BPDE3AABCC4PDE2A
SCHEMBL12989016 0.91 PDE5A (0.54) PDE5APDE3BPDE3AABCC4PDE2A
Iodide SCHEMBL17063157 0.90 PDE5A (0.54) PDE5APDE3BPDE3AABCC4PDE2A
SCHEMBL15640034 0.90 PDE5A (0.54) PDE5APDE3BPDE3AABCC4PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9359376-B2 Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds SPHAERA PHARMA PTE. LTD (SG) 2016-06-07 — — US claimed
US-20140121367-A1 SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS PIVOT HOLDING LLC 2014-05-01 — — US claimed
EP-2693876-A1 SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS Sphaera Pharma Pte. Ltd (SG) 2014-02-12 — — EP claimed
WO-2012137225-A1 SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS SPHAERA PHARMA PVT. LTD (IN) 2012-10-11 — — WO claimed
US-9556156-B2 Compounds, their synthesis and their uses Sphaera Pharma Pte Ltd. (SG) 2017-01-31 — — US disclosed
US-9359376-B2 Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds SPHAERA PHARMA PTE. LTD (SG) 2016-06-07 — — US disclosed
US-9359376-B2 Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds SPHAERA PHARMA PTE. LTD (SG) 2016-06-07 — — US disclosed
US-20150252027-A1 NOVEL COMPOUNDS, THEIR SYNTHESIS AND THEIR USES Sphaera Pharma Pte Ltd. (SG) 2015-09-10 — — US disclosed
US-20140121367-A1 SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS PIVOT HOLDING LLC 2014-05-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140121367-A1 SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS TPMT, BHMT2, PFAS PDE5A 819/4885PDE3B 863/4885PDE3A 803/4885
US-20150252027-A1 NOVEL COMPOUNDS, THEIR SYNTHESIS AND THEIR USES NR0B1, CYP2B6, NR2E1 PDE5A 3269/4885PDE3B 3119/4885PDE3A 3738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback